GENENTECH, INC.
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT03916744
- Locations
- π§πͺ
Clinique Sainte-Elisabeth; Oncologie, Namur, Belgium
πΊπΈUniversity of Colorado, Aurora, Colorado, United States
πͺπΈHM Sanchinarro ? CIOCC, Madrid, Spain
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
- Conditions
- Chronic Idiopathic PruritusChronic Idiopathic UrticariaLichen Simplex ChronicusPlaque PsoriasisLichen Planus
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03858634
- Locations
- πΊπΈ
Site 106, Anniston, Alabama, United States
πΊπΈSite 110, Phoenix, Arizona, United States
πΊπΈSite 114, Hot Springs, Arkansas, United States
A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT03828747
- Locations
- πΊπΈ
Miami Jewish Health Systems, Miami, Florida, United States
πΊπΈPharmacology Research Institute, Los Alamitos, California, United States
πΊπΈCollier Neurologic Specialists, Naples, Florida, United States
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT03815058
- Locations
- πΊπΈ
Seattle Cancer Care Alliance, Seattle, Washington, United States
π¦πΊLiverpool Hospital, Liverpool, New South Wales, Australia
πΊπΈAtlanta Cancer Care, Alpharetta, Georgia, United States
A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03807739
- Locations
- πΊπΈ
Covance Research Unit - Dallas, Dallas, Texas, United States
πΊπΈCovance Research Unit - Daytona, Daytona Beach, Florida, United States
A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT03796013
- Locations
- πΊπΈ
Covance Research Unit - Dallas, Dallas, Texas, United States
A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03796260
- Locations
- πΊπΈ
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
- Conditions
- THROMBOLYSIS
- Interventions
- Other: PlaceboBiological: Tenecteplase
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 458
- Registration Number
- NCT03785678
- Locations
- πΊπΈ
Kaiser Permanente Los Angeles, Los Angeles, California, United States
πΊπΈUniversity of Southern California Medical Center, Los Angeles, California, United States
πΊπΈCedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT03747575
- Locations
- πΊπΈ
Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States
πΊπΈSkin Laser and Surgery Specialists of New York and New Jersey LLC - Interspond - PPDS, Hackensack, New Jersey, United States
πΊπΈHarmony Clinical Research, Inc, North Miami Beach, Florida, United States
A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT03693625
- Locations
- πΊπΈ
Allergy & Asthma Immunology Associates, Scottsdale, Arizona, United States
πΊπΈKern Allergy Med Clinic, Inc., Bakersfield, California, United States
πΊπΈIntegrated Research Group Inc, Riverside, California, United States